Malignant Respiratory System Neoplasm

In a retrospective study of 2316 Chinese patients with stage IV non-small cell lung carcinoma, a 63 year old female with the EGFR exon 20 insertion A767_V769dupASV received osimertinib as first-line t… (full text at CIViC)

PMID 31208370 · Fang et al., 2019 · Open in CIViC

In a lung adenocarcinoma patient harboring EGFR A859T mutation, EGFR A859T was reported to be sensitive to erlotinib treatment. The patient was initially treated with standard chemotherapy and subsequ… (full text at CIViC)

PMID 21317745 · Le Maignan et al., 2011 · Open in CIViC

In an in vitro study, a MCF-7 cell line expressing EGFR A859T demonstrated reduced sensitivity to erlotinib treatment compared to MCF-7 cells expressing EGFR L858R (a known sensitizing mutation to EGF… (full text at CIViC)

PMID 17877814 · de Gunst et al., 2007 · Open in CIViC

In an in vitro study, a Ba/F3 cell line expressing EGFR A864T demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). … (full text at CIViC)

PMID 19147750 · Kancha et al., 2009 · Open in CIViC

NSCLC with EGFR activating alterations are frequently treated with the tyrosine kinase inhibitor, osimertinib. Though initially very effective, cancers cells often develop resistance to osimertinib th… (full text at CIViC)

PMID 37481710 · Lu et al., 2023 · Open in CIViC

A meta-analysis of EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment was performed. In total, 20 (1689 patients, 594 with increased gene copy n… (full text at CIViC)

PMID 20826716 · Dahabreh et al., 2011 · Open in CIViC

Study was a Phase 3 clinical trial of erlotinib in non-small cell lung cancer patients who has progressed after standard chemotherapy. Study found significantly increased survival time for patients… (full text at CIViC)

PMID 16014883 · Tsao et al., 2005 · Open in CIViC

Five patients with acquired resistance to crizotinib showed high concentration of amphiregulin in malignant pleural effusions.

PMID 23344087 · Kim et al., 2013 · Open in CIViC

A cell line (DFCI076 ) with EML1-ALK fusion and resistance mutation L1152R showed no response to ALK inhibition with crizotinib or TAE684. There was co-dependancy on AKT and EGFR-signaling and inhibit… (full text at CIViC)

PMID 21791641 · Sasaki et al., 2011 · Open in CIViC

A genetically engineered mouse model of lung adenocarcinoma (LUAD) was created expressing human EGFR L858R+T790M transgene. Twenty of 49 mice treated with osimertinib developed treatment-resistant tum… (full text at CIViC)

PMID 32193290 · Starrett et al., 2020 · Open in CIViC

Third generation EGFR inhibitor osimertinib can overcome the T790M resistance mutation on L858R or exon 19 del background. Drug screening of Ba/F3 cells expressing EGFR triple mutant (C797S/T790M/del1… (full text at CIViC)

PMID 28287083 · Uchibori et al., 2017 · Open in CIViC

Currently, there are no effective therapeutic strategies to overcome the C797S/T790M/activating-mutation (triple-mutation)-mediated EGFR-TKI resistance to Osimertinib. In the present study, we identif… (full text at CIViC)

PMID 28287083 · Uchibori et al., 2017 · Open in CIViC

D761Y as a secondary mutation was reported to be associated with resistance to gefitinib and erlotinib in NSCLC cells that contain the L858R-EGFR mutation. This mutation combination was observed in a … (full text at CIViC)

PMID 17085664 · Balak et al., 2006 · Open in CIViC

In a study of 19 non-small cell lung carcinoma patients with EGFR exon 20 insertion mutation and treated with erlotinib monotherapy, patients with EGFR D770delinsGY mutation (n=2) experienced progress… (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

2 patients with EGFR delD770insGY mutant lung adenocarcinoma were treated with first line erlotinib. A 76 year old female 6 pack year former smoker had progressive disease as best response with +38.1%… (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

In a multinational open label phase II dose randomized study of sunvozertinib in platinum pretreated advanced NSCLC with EGFR exon 20 insertion mutations (WU-KONG1B, NCT03974022; efficacy n = 85 for 2… (full text at CIViC)

PMID 40923280 · Yang et al., 2025 · Open in CIViC

In a retrospective study of 2316 Chinese patients with stage IV non-small cell lung carcinoma, a 63 year old female with the EGFR exon 20 insertion D770_N771insG received osimertinib as second-line tr… (full text at CIViC)

PMID 31208370 · Fang et al., 2019 · Open in CIViC

2 patients with EGFR D770_N771insGL mutant lung adenocarcinoma were treated with first line erlotinib. A 45 year old male never smoker had progressive disease as best response with +24% change to tar… (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

In a lung adenocarcinoma patient harboring EGFR D770_N771insGT mutation, EGFR D770_N771insGT was associated with lack of response to treatment with erlotinib monotherapy.

PMID 23371856 · Arcila et al., 2013 · Open in CIViC

In a multinational open label phase II dose randomized study of sunvozertinib in platinum pretreated advanced NSCLC with EGFR exon 20 insertion mutations (WU-KONG1B, NCT03974022; efficacy n = 85 for 2… (full text at CIViC)

PMID 40923280 · Yang et al., 2025 · Open in CIViC

In an in vitro study, a Ba/F3 cell line expressing EGFR D770_N771insNPG demonstrated reduced sensitivity to erlotinib treatment (IC50=2.139�M), comparable to Ba/F3 cells expressing EGFR L858R and T790… (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

Ba/F3 cells transduced with EGFR D770_N771insNPG were IL3 growth independent, suggesting a driver mutation. Gefitinib growth inhibition IC50 in D770_N771insNPG transduced Ba/F3 cells was 3.356 micro … (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

2 patients with EGFR D770_N771insSVD positive lung adenocarcinoma were treated with erlotinib tyrosine kinase inhibitor as first line treatment. A 66 year old female never smoker had stable disease a… (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

In an in vitro study, a Ba/F3 cell line expressing EGFR D770_N771insSVD demonstrated reduced sensitivity to erlotinib treatment (IC50=3.187�M), comparable to Ba/F3 cells expressing EGFR L858R and T790… (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

Two uncommon EGFR frameshift deletions (E701fs and L702fs; VAFs of 32.8% and 21.5%, respectively) were identified by NGS in a patient with NSCLC. The patient was enrolled in the OCELOT clinical trial … (full text at CIViC)

PMID 41590375 · Wong et al., 2026 · Open in CIViC

Patient with E709Q add a PR response under Gefinitb treatment.

PMID 15897572 · Chou et al., 2005 · Open in CIViC

In a stage IV lung adenocarcinoma patient with EGFR E709_T710>D mutation, EGFR E709_T710>D was reported to be sensitive to erlotinib treatment. The patient was treated with erlotinib monotherapy and a… (full text at CIViC)

PMID 22982663 · Ackerman et al., 2012 · Open in CIViC

In a study, 2 participants with stage IV lung adenocarcinoma were sequenced at EGFR exons 18 to 21. Both patients were found to have DelE709-T710 insD mutation and were treated with the 1st generatio… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

In a phase 2b/3 study of 585 lung adenocarcinoma patients who had a previous round of EGFR-TKI treatment, archival material was available for 141 patients. EGFR mutational analysis revealed that 96 tu… (full text at CIViC)

PMID 22452896 · Miller et al., 2012 · Open in CIViC

A phase 3 study of 345 stage IIIB-IV lung adenocarcinoma patients, reported improved median progression free survival (13.6 months vs. 6.9 months, HR: 0.47, 95% CI: 0.34-0.65, P=0.001) in EGFR mutatio… (full text at CIViC)

PMID 23816960 · Sequist et al., 2013 · Open in CIViC